Release date: September 30, 2009
Expiration date: September 30, 2010
Estimated time to complete this activity: 1.5 hours
Target Learners:
This activity is intended for rheumatologists.
Learning Objectives
After completing this activity, participants should be able to:
Choose treatment options considering inflammatory pathways underlying clinical disease.
Select treatment options that improve outcomes and reduce toxicity for RA patients with comorbid conditions.
Evaluate the efficacy and safety of new and emerging agents for the treatment of patients with rheumatoid arthritis.
Consider how new therapies may change RA treatment.
Faculty
Arthur Kavanaugh, MD (Chair)
Director, Center for Innovative Therapy
Professor of Medicine
Division of Rheumatology, Allergy, and Immunology
University of California San Diego
La Jolla, CA
Christopher Ritchlin, MD
Professor of Medicine
Director, Translational Immunology Center
University of Rochester Medical Center
Rochester, NY
Nora Singer, MD
Assistant Professor, Department of Pediatrics
Division of Infectious Diseases, Immunology, and Rheumatology
Case Western University
Cleveland, OH
Accreditation Statement
This activity was planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Interstate Postgraduate Medical Association and MEV Healthcom, Inc. Interstate Postgraduate Medical Association is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation
Interstate Postgraduate Medical Association designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credit(s).
Physicians should only claim credit commensurate with the extent of their participation in the activity.
Commercial Support
Interstate Postgraduate Medical Association and MEV Healthcom, Inc., gratefully acknowledge Roche for providing an educational grant in support of this activity.
Method of Participation
Physician learners will participate in this educational activity by reading this education content, completing the post-test and evaluation. Learners must complete a post-test and evaluation and receive a passing score of 70% or more on the post-test. This activity should take 1.5 hours to complete.
Faculty and Planners Disclosure Statement
As a provider dedicated to independent education and accredited by the ACCME, Interstate Postgraduate Medical Association (IPMA) must ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. It is the policy of IPMA to require disclosure of the existence of any significant financial interest or other relationship a faculty member, planner, or a sponsor has with either the commercial supporter of this activity or the manufacturer(s) of any commercial product(s) discussed in an educational presentation.
Faculty Disclosures
Arthur Kavanaugh, MD, Consultant Roche, Abbott, Centocor, UCB, Genentech; Research Roche, Abbott, Centocor, UCB, Genentech.
Christopher Ritchlin, MD, Consultant Centocor, Amgen, Abbott, Bristol-Myers Squibb; Research Centocor.
Nora Singer, MD, Speaker's Bureau Abbott; Consultant Abbott, Vienna Medical.
Planner Disclosures
Mary W. Ales, Investment-Amgen.
No other planners or staff who could influence the content of this activity have any relations with relevant commercial interests to disclose.
Writer
Barbara L. Jones, MA, reported no relevant commercial relationships.
Independent Reviewers
John F. Schneider, MD, PhD nothing to disclose.
Alan J. Bridges, MD Speaker/Teacher Abbott Laboratories, Biogen, Bristol-Myers Squibb, Genentech, Inc.
Disclosure of Off-Label Use
Some of the information contained herein may cite the off-label use of drugs. Consult the approved package insert(s) for complete prescribing information. Tocilizumab, ocrelizumab, ofatumumab, epratuzumab, tamatinib, ustekinumab, apilimod, pamipimod, alefacept, efalizumab, natalizumab, belimumab, ABT-874, and denosumab are investigational drugs not approved by the FDA.
On April 3, 2009, when the "live" symposium took place, certolizumab pegol and golimumab were not approved. As of this publication, they received FDA approval.
Disclaimer
The views expressed in this activity are those of the faculty. It should not be inferred or assumed that the faculty are expressing the views of the Interstate Postgraduate Medical Association, MEV Healthcom, Inc., or any other company.
Peer Review
This activity has been reviewed by a physician of the target audience.
Privacy Policy
At Interstate Postgraduate Medical Association (IPMA) we care about providing you with tools and information to manage and protect your online privacy. IPMA retains records solely for keeping records in accordance with ACCME policies. We will not share your information with any other organizations. We will keep you informed of our CME activities.
Please email cmehelp@ipmameded.org if you do not want to receive any communications from us.
Copyright
All material on this website is protects by copyright. Copyright 2009 by IPMA. This also contains material copyrighted by 3rd parties.
Contact Information
IPMA
PO Box 5474
Madison, WI 53705
608.231.9045 fax 877.292.4489
cmehelp@ipmameded.org
Review Activity Online Post Test